Meloxicam, Rizatriptan + PropranololContraindicated
Propranolol has been shown to increase the plasma AUC of rizatriptan. The concomitant use of SYMBRAVO with propranolol is contraindicated.
Source: FDA drug label - meloxicam, rizatriptan
Meloxicam, Rizatriptan Interactions
Brand names: Symbravo
Nonsteroidal Anti-inflammatory Drug · Cyclooxygenase Inhibitors
FDA Black Box Warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings & Precautions (5.1) ] . SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) , Warnings & Precautions (5.1) ] . Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings & Precautions (5.2) ] . WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1) . SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ). NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ( 5.2 ).
3 interactions on record
Thus, concomitant usage of CYP2C9 inhibitors (e.g., amiodarone, fluconazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [see Use in Specific Populations (8.8) , Clinical Pharmacology (12.3, 12.5)] .
Source: FDA drug label - meloxicam, rizatriptan
Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Diuretics Clinical Impact Clinical studies, as well as postmarketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. However, studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect.
Source: FDA drug label - meloxicam, rizatriptan